Armored cells take on tough lymphoma in early trial
NCT ID NCT07368270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new type of immune cell therapy called anti-PD1 armored CD19 CAR-T cells in 30 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. The cells are designed to better attack cancer and resist exhaustion. The main goal is to check safety and find the right dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-PD1 armored CD19 CAR-T cells
- What this could lead to
- If successful, this could lead to a more effective treatment for hard-to-treat lymphoma by helping the immune system fight cancer longer.
- What could go wrong
- This is an early Phase 1 trial with only 30 people, so safety and effectiveness are not yet proven. Side effects like cytokine release syndrome or nerve problems are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Suzhou Hongci Hematology Hospital
RECRUITINGSuzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells plus a checkpoint drug outsmart lymphoma?
- Can an immune booster outsmart brain lymphoma?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?
- Can a Light-Based device spot dangerous infection risk without a blood draw?